Cancer Cell Secretion of the DAMP Protein HMGB1 Supports Progression in Malignant Mesothelioma
- 1 July 2012
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 72 (13), 3290-3301
- https://doi.org/10.1158/0008-5472.can-11-3481
Abstract
Human malignant mesothelioma is an aggressive and highly lethal cancer that is believed to be caused by chronic exposure to asbestos and erionite. Prognosis for this cancer is generally poor because of late-stage diagnosis and resistance to current conventional therapies. The damage-associated molecular pattern protein HMGB1 has been implicated previously in transformation of mesothelial cells. Here we show that HMGB1 establishes an autocrine circuit in malignant mesothelioma cells that influences their proliferation and survival. Malignant mesothelioma cells strongly expressed HMGB1 and secreted it at high levels in vitro. Accordingly, HMGB1 levels in malignant mesothelioma patient sera were higher than that found in healthy individuals. The motility, survival, and anchorage-independent growth of HMGB1-secreting malignant mesothelioma cells was inhibited in vitro by treatment with monoclonal antibodies directed against HMGB1 or against the receptor for advanced glycation end products, a putative HMGB1 receptor. HMGB1 inhibition in vivo reduced the growth of malignant mesothelioma xenografts in severe-combined immunodeficient mice and extended host survival. Taken together, our findings indicate that malignant mesothelioma cells rely on HMGB1, and they offer a preclinical proof-of-principle that antibody-mediated ablation of HMBG1 is sufficient to elicit therapeutic activity, suggesting a novel therapeutic approach for malignant mesothelioma treatment. Cancer Res; 72(13); 3290–301. ©2012 AACR.Keywords
Other Versions
This publication has 43 references indexed in Scilit:
- HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4The Journal of Experimental Medicine, 2012
- Molecular Pathways: Targeting Mechanisms of Asbestos and Erionite Carcinogenesis in MesotheliomaClinical Cancer Research, 2012
- Germline BAP1 mutations predispose to malignant mesotheliomaNature Genetics, 2011
- Erionite exposure in North Dakota and Turkish villages with mesotheliomaProceedings of the National Academy of Sciences of the United States of America, 2011
- Malignant mesothelioma: Facts, Myths, and HypothesesJournal of Cellular Physiology, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammationProceedings of the National Academy of Sciences of the United States of America, 2010
- Mesothelioma Epidemiology, Carcinogenesis, and PathogenesisCurrent Treatment Options in Oncology, 2008
- HMGB1 release induced by liver ischemia involves Toll-like receptor 4–dependent reactive oxygen species production and calcium-mediated signalingThe Journal of Experimental Medicine, 2007
- TNF-α inhibits asbestos-induced cytotoxicity via a NF-κB-dependent pathway, a possible mechanism for asbestos-induced oncogenesisProceedings of the National Academy of Sciences of the United States of America, 2006